Association between the Use of Macrolide Antibiotics and Recurrent Wheezing in Hospitalized Infants with Bronchiolitis

Author(s)

Suh HS1, Jang S2
1College of Pharmacy, Kyung Hee University, Department of Regulatory Science, Graduate School, Kyung Hee University, Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul, Korea, Republic of (South), 2Department of Regulatory Science, Graduate School, Kyung Hee University, Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul, Korea, Republic of (South)

OBJECTIVES: This study aims to evaluate the impact of macrolide antibiotic use on the risk of recurrent wheezing in infants hospitalized with bronchiolitis, a common but serious respiratory condition in infants.

METHODS: A retrospective cohort study was conducted using nationwide claims data from the Health Insurance Review and Assessment Service. We identified infants aged <1 year hospitalized for bronchiolitis (J21.0-J21.9, ICD-10 code) between 2017.01-2022.04. Participants were divided into 2 groups: patients who received macrolide antibiotics within 2 days of hospitalization (macrolide antibiotic (MA) group) and patients who did not received any antibiotics during the 1st year of life (control group). Patients who were previously diagnosed with wheeze, high-risk disease, or risk factors of wheezing before index were excluded. For ensuring comparability between groups, 1:1 greedy matching was used for propensity score matching method. The incidence of recurrent wheezing was estimated using Kaplan-Meier curve, and hazard ratio of recurrent wheezing by Cox proportional hazard model. The log-minus-log survival plot and Schoenfeld’s residual were obtained to assess proportional hazard assumption.

RESULTS: The study included 1,107 subjects in each group after matching. In control group, mean age was 3.31 months with 55.19% male. In MA group, mean age was 3.41 months with 54.74% male. The incidence of recurrent wheezing was significantly higher in the MA group (188.07 per 1,000 patient-years) compared to the control group (93.38 per 1,000 patient-years). The risk of recurrent wheezing was 2.06 times higher in the MA group (HR 2.06, 95% CI 1.77-2.36, p<0.0001), with the proportional hazard assumption confirmed as not violated.

CONCLUSIONS: This study suggests a potential association between macrolide antibiotic use and an increased risk of recurrent wheezing in infants hospitalized with bronchiolitis. These findings highlight the need for careful use and reassessment of macrolide antibiotics in the treatment of bronchiolitis.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

EPH14

Topic

Epidemiology & Public Health

Topic Subcategory

Safety & Pharmacoepidemiology

Disease

Drugs, Pediatrics, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×